These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36514450)

  • 1. Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Amjad W; Malik A; Qureshi W; Dennis B; Mumtaz M; Haider R; Jamal S; Jaura F; Ahmed A
    Prz Gastroenterol; 2022; 17(4):288-300. PubMed ID: 36514450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Hameed I; Hayat J; Marsia S; Samad SA; Khan R; Siddiqui OM; Khan MO; Malik S; Fatima K; Fudim M; Krasuski RA
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102111. PubMed ID: 36931466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
    Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
    Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
    Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis.
    Ong Lopez AMC; Pajimna JAT
    Sci Rep; 2024 Jan; 14(1):2122. PubMed ID: 38267513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
    Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
    World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.
    Raj H; Durgia H; Palui R; Kamalanathan S; Selvarajan S; Kar SS; Sahoo J
    World J Diabetes; 2019 Feb; 10(2):114-132. PubMed ID: 30788048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
    Fatima K; Moeed A; Waqar E; Atif AR; Kamran A; Rizvi H; Suri NF; Haider H; Shuja SH; Khalid M; Minhas AMK
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101816. PubMed ID: 34607067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.
    Kumar J; Memon RS; Shahid I; Rizwan T; Zaman M; Menezes RG; Kumar S; Siddiqi TJ; Usman MS
    Dig Liver Dis; 2021 Jan; 53(1):44-51. PubMed ID: 32912770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    Wang X; Wu N; Sun C; Jin D; Lu H
    Diabetol Metab Syndr; 2023 May; 15(1):113. PubMed ID: 37254186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    Wei Q; Xu X; Guo L; Li J; Li L
    Front Endocrinol (Lausanne); 2021; 12():635556. PubMed ID: 34220701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data.
    Arai T; Atsukawa M; Tsubota A; Mikami S; Ono H; Kawano T; Yoshida Y; Tanabe T; Okubo T; Hayama K; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kaneko K; Emoto N; Nagao M; Inagaki K; Fukuda I; Sugihara H; Iwakiri K
    Ther Adv Endocrinol Metab; 2021; 12():20420188211000243. PubMed ID: 33815743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for Assessing Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter 2 Inhibitor Therapy.
    Khaznadar F; Petrovic A; Khaznadar O; Roguljic H; Bojanic K; Kuna Roguljic L; Siber S; Smolic R; Bilic-Curcic I; Wu GY; Smolic M
    J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials.
    Ng CH; Lin SY; Chin YH; Lee MH; Syn N; Goh XL; Koh JH; Quek J; Hao Tan DJ; Mok SF; Tan E; Dan YY; Chew N; Khoo CM; Siddiqui MS; Muthiah M
    Endocr Pract; 2022 Feb; 28(2):223-230. PubMed ID: 34606980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review.
    Dwinata M; Putera DD; Hasan I; Raharjo M
    Clin Exp Hepatol; 2020 Dec; 6(4):339-346. PubMed ID: 33511282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials.
    Lee KW; Devaraj NK; Ching SM; Veettil SK; Hoo FK; Deuraseh I; Soo MJ
    Oman Med J; 2021 May; 36(3):e273. PubMed ID: 34239714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews.
    Shao SC; Kuo LT; Chien RN; Hung MJ; Lai EC
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33268450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials.
    Coelho FDS; Borges-Canha M; von Hafe M; Neves JS; Vale C; Leite AR; Carvalho D; Leite-Moreira A
    Diabetes Metab Res Rev; 2021 Sep; 37(6):e3413. PubMed ID: 33010191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.